Research Article

Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts

Figure 2

Schedule of imaging experiments, ex vivo validations on excised tumor tissue and therapy scheme. Thirty days after inoculation of JIMT1 and SKOV3 cells, mice underwent an [18F]FDG PET scan. Longitudinal [18F]FDG PET imaging was performed at baseline (day 0) and after start of therapy on day 2 (d2) and on day 7 (d7). After the baseline scans, treatment was initiated with control, trastuzumab, everolimus, or PIK90. The combination groups received trastuzumab+everolimus or trastuzumab+PIK90 or everolimus+PIK90 or trastuzumab+everolimus+PIK90.